Full Press Release Details
Therapeutics Approved for Listing on NASDAQ Capital Market
common stock will begin trading on December 10, 2007(and not December 11, 2007
as previously announced)
YORK-- (BUSINESS WIRE)--Pluristem Therapeutics Inc. (OTCBB: PSTI.OB - DAX:
a leading bio-therapeutics company dedicated to the commercialization of
non-personalized (allogeneic) cell therapy products for a variety of malignant,
ischemic and auto-immune disorders, announced today that NASDAQ has approved
Company's application to list its securities on the NASDAQ Capital Market. The
Company's common stock will begin trading on December 10, 2007 (and not December
11, 2007 as previously announced) under the symbol PSTI.
Aberman, Pluristem's President and CEO commented, "Pluristem is proud to begin
trading on the NASDAQ Capital Market system. We believe that NASDAQ is the
platform to support our business growth aspirations. I am confident that our
listing will facilitate broader interest in our common stock from both
institutional and individual investors."
NASDAQ listing approval is contingent upon the Company being in compliance
all applicable listing standards on the date it begins trading on NASDAQ,
including that the trading price of the Company's common stock remain at $4.00
or more, and may be rescinded if the Company is not in compliance with such
Therapeutics, Inc. is a Company dedicated to the commercialization of
non-personalized (allogeneic) stem cell therapy products for the treatment
numerous severe degenerative, malignant and autoimmune disorders. The Company's
first product, PLX-I, is directed at resolving the global shortfall of matched
tissue for bone marrow transplantation (BMT) by improving the engraftment of
hematopoietic stem cells (HSCs) contained in umbilical cord blood
products are derived from mesenchymal stromal cells (MSCs) obtained from the
placenta and not from embryonic stem cells. They are expanded in the Company's
proprietary PluriXTM
bioreactor that imitates the natural microstructure of bone marrow and does
require supplemental growth factors, cytokines or other exogenous materials.
Pluristem believes the resultant expanded cells, termed PLX cells, are
multi-potent and able to differentiate into a variety of cell types. Recent
evidence also suggests their efficacy may be related to their secretion of
cytokines or other potent immune modulators. Furthermore, PLX cells are believed
to be immune-privileged, hence protecting the recipient from immunological
reactions that often accompany transplantation.
has offices in the USA with research and manufacturing facilities in
press release contains forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation Reform Act of
and federal securities laws. These forward-looking statements are based on
current expectations of the management of Pluristem only, and are subject to
number of factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements. For example,
when we discuss the effect of our expected listing on NASDAQ, we are using
forward looking statement. The following factors, among others, could cause
actual results to differ materially from those described in the forward-looking
statements: changes in technology and market requirements; our technology may
not be validated as we progress further and our methods may not be accepted
the scientific community; we may be unable to retain or attract key employees
whose knowledge is essential to the development of our products; unforeseen
scientific difficulties may develop with our process; results in the laboratory
may not translate to equally good results in real surgical settings; our patents
may not be sufficient ;our products may harm recipients; changes in legislation;
inability to timely develop and introduce new technologies, products and
applications; loss of market share and pressure on pricing resulting from
competition, which could cause the actual results or performance of Pluristem
differ materially from those contemplated in such forward-looking statements.
Except as otherwise required by law, Pluristem undertakes no obligation to
publicly release any revisions to these forward-looking statements to reflect
events or circumstances after the date hereof or to reflect the occurrence
unanticipated events. For a more detailed description of the risk and
uncertainties affecting Pluristem, reference is made to Pluristem's reports
filed from time to time with the Securities and Exchange
information visit our website at www.pluristem.com,
content of which is not part of this press release.
Prather, 303-883-4954
Corporate Development
Pluristem Therapeutics Inc.